Prosecution Insights
Last updated: November 12, 2026
Application No. 18/898,899

PUPILLARY BIOMARKERS TO ASSESS EFFECTS OF PSYCHOTROPIC DRUGS

Non-Final OA §102
Filed
Sep 27, 2024
Priority
Sep 01, 2023 — provisional 63/536,097
Examiner
MOSER, SETH DAVID
Art Unit
2872
Tech Center
2800 — Semiconductors & Electrical Systems
Assignee
Neuroptics Inc.
OA Round
1 (Non-Final)
98%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 98% — above average
98%
Career Allowance Rate
44 granted / 45 resolved
+29.8% vs TC avg
Minimal +3% lift
Without
With
+2.6%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
3 currently pending
Career history
56
Total Applications
across all art units

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-6 are rejected under 35 U.S.C. 102(a)(1)&(a)(2) as being anticipated by US 20170100061 A1 (Finkel). Regarding claim 1: Finkel discloses a method of assessing the effectiveness of a psychotropic drug on a mammalian subject (Para. [0073], the method is used to track pupillary changes and dose-ranging effects during treatment with psychotropic drugs.), said method comprising: providing a pupilometer (Fig. 13A and Para. [0086], a smartphone with attachments [1302] is used as a pupilometer.); using the pupilometer to obtain pupillary biomarker data from at least one pupil of the subject before the subject is administered the psychotropic drug (Fig. 7 and Para. [0069], PRD curve [710] relating to a baseline before the administration of a psychotropic drug (hydromorphone)); using the pupilometer to obtain pupillary biomarker data from at least one pupil of the subject after the subject is administered the psychotropic drug (Fig. 7 and Para. [0069], PRD curves [720], [730], and [740] taken at different times after the administration of a psychotropic drug (hydromorphone)); using the pupilometer to process all of the pupillary biomarker data (Para. [0036], components to capture and process image data of the eye.); displaying an output that indicates the effectiveness of the psychotropic drug. (Para. [0070], the analyzed data is used to determine tolerance and dose effects. Para. [0073], the method is used to track pupillary changes and dose-ranging effects during treatment with psychotropic drugs. Fig. [13A] GUI [1308] and Para. [0088], the GUI [1308] displays the processed data) Regarding claim 2: Finkel discloses a method of assessing the effectiveness of a psychotropic drug on a mammalian subject (Para. [0073], the method is used to track pupillary changes and dose-ranging effects during treatment with psychotropic drugs.), said method comprising: providing a pupilometer having a display (Fig. [13A], GUI [1308] and Para. [0088] and [0086], a smartphone with attachments [1302] is used as a pupilometer and the GUI [1308] displays the processed data), said pupilometer having access to a dataset of pupillary biomarker data obtained from subjects other than the subject (Fig. 14, step [S1401] involves generating biomarker signatures for comparison to the subjects biomarker data in step [S1407], this is done using biomarker data from other subjects); using the pupilometer to obtain pupillary biomarker data from at least one pupil of the subject; (Fig. 7 and Para. [0069], PRD curves [720], [730], and [740] taken at different times after the administration of a psychotropic drug (hydromorphone)) using the pupilometer to process all of the pupillary biomarker data (Para. [0036], components to capture and process image data of the eye.); displaying an output on the display of the pupilometer that indicates the effectiveness of the psychotropic drug. (Para. [0070], the analyzed data is used to determine tolerance and dose effects. Para. [0073], the method is used to track pupillary changes and dose-ranging effects during treatment with psychotropic drugs. Fig. [13A] GUI [1308] and Para. [0088], the GUI [1308] displays the processed data) Regarding claim 3: Finkel discloses a program product comprising a computer-readable medium and computer- executable instructions recorded on the computer-readable medium for performing a method of assessing the effectiveness of a psychotropic drug on a mammalian subject (Para. [0110]-[0111], the functions in the embodiments are implemented by a programmed processor using instructions from computer-readable memory.), wherein the method comprises: causing a pupilometer having a display to obtain pupillary biomarker data from at least one pupil of the subject before the subject is administered the psychotropic drug; (Fig. 7 and Para. [0069], PRD curve [710] relating to a baseline before the administration of a psychotropic drug (hydromorphone)) causing the pupilometer to obtain pupillary biomarker data from at least one pupil of the subject after the subject is administered the psychotropic drug (Fig. 7 and Para. [0069], PRD curves [720], [730], and [740] taken at different times after the administration of a psychotropic drug (hydromorphone)); causing the pupilometer to process all of the pupillary biomarker data (Para. [0036], components to capture and process image data of the eye.); causing the pupilometer to display on its display an output that indicates the effectiveness of the psychotropic drug. (Para. [0070], the analyzed data is used to determine tolerance and dose effects. Para. [0073], the method is used to track pupillary changes and dose-ranging effects during treatment with psychotropic drugs. Fig. [13A] GUI [1308] and Para. [0088], the GUI [1308] displays the processed data) Regarding claim 4: Finkel discloses a program product comprising a computer-readable medium and computer- executable instructions recorded on the computer-readable medium for performing a method of assessing the effectiveness of a psychotropic drug on a mammalian subject (Para. [0110]-[0111], the functions in the embodiments are implemented by a programmed processor using instructions from computer-readable memory.), wherein the method comprises: causing a pupilometer to access a dataset of pupillary biomarker data obtained from subjects other than the subject (Fig. 14, step [S1401] involves generating biomarker signatures for comparison to the subjects biomarker data in step [S1407], this is done using biomarker data from other subjects); causing the pupilometer to obtain pupillary biomarker data from at least one pupil of the subject (Fig. 7 and Para. [0069], PRD curves [720], [730], and [740] taken at different times after the administration of a psychotropic drug (hydromorphone)); causing the pupilometer to process all of the pupillary biomarker data (Para. [0036], components to capture and process image data of the eye.); causing the pupilometer to display on its display an output that indicates the effectiveness of the psychotropic drug. (Para. [0070], the analyzed data is used to determine tolerance and dose effects. Para. [0073], the method is used to track pupillary changes and dose-ranging effects during treatment with psychotropic drugs. Fig. [13A] GUI [1308] and Para. [0088], the GUI [1308] displays the processed data) Regarding claim 5: Finkel discloses a pupilometer (Fig. 13A and Para. [0086], a smartphone with attachments [1302] is used as a pupilometer.); comprising: a light source for generating and emitting a light stimulus to stimulate a pupil of a mammalian subject (Para. [0097], the light stimulus is generated by the smartphone camera flash.); a camera for recording and measuring a dynamic response of said pupil to the light stimulus (Fig. 13 and para. [0087], image capture [1304] is used to measure PRD (pupillary reflex dilation)); a memory that can store data relating to the dynamic response of the pupil to the light stimulus (Fig. 13A showing the smartphone has memory [CPU/Memory] and Para. [0088], the data may be stored on the phone.); a microprocessor that can process data obtained from a pupil prior to the subject being administered a psychotropic drug and data obtained from a pupil after the subject is administered a psychotropic drug and provide an output indicative of the effectiveness of the psychotropic drug (Para. [0088] the smartphone, having a microprocessor [CPU/Memory], is configured to analyze and display the data from the subject. Also see Fig. 7 and Para. [0069], discussing PRD curve [710] taken before the administration of the psychotropic drug and PRD curves [720], [730], and [740] taken after.). Regarding claim 6: Finkel discloses the pupilometer of claim 5, further comprising a display for displaying the output indicative of the effectiveness of the psychotropic drug. (Fig. [13A] GUI [1308] and Para. [0088], the GUI [1308] displays the processed data.) Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. US 20150116665 A1 (Finkel) See para. [0063], used for tracking pupillary changes before and during treatment to guide the treatment. US 20190191995 A1 (Giovinazzo et al.) Para. [0095]-[0100], Steps of a method to use pupil data to determine the presence of psychotropic substances in a subject by comparing to pupil data from other test subjects. US 20160183784 A1 (Privitera et al.) Discloses a similar pupilometer to claim 5. See also Para. [0015] discussing it’s use in determining drug impairment or intoxication. Malone, D. A. et al. Ophthalmologic Effects of Psychotropic Medications Psychosomatics, Vol. 33, no. 3 (August 1992), pp. 271-277. ISSN 0033-3182. (Malone et al.) Discusses various ophthalmologic effects of psychotropic drugs. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SETH D MOSER whose telephone number is (703)756-5803. The examiner can normally be reached Mon-Fri, 10am-6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bumsuk Won can be reached at (571)270-1782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SETH D MOSER/Examiner, Art Unit 2872 /BALRAM T PARBADIA/Primary Examiner, Art Unit 2872
Read full office action

Prosecution Timeline

Sep 27, 2024
Application Filed
Oct 28, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12782669
VEHICULAR IMAGING DEVICE
2y 7m to grant Granted Nov 03, 2026
Patent 12765769
Eye Tracking Apparatus and Eye Tracking Method
2y 4m to grant Granted Oct 20, 2026
Patent 12761503
AN ASSEMBLY FOR PRESSING AGAINST EACH OTHER TWO OPHTHALMIC LENSES IN ORDER TO BUILD AN ELECTROCHROMIC CELL
2y 10m to grant Granted Oct 13, 2026
Patent 12761500
LENS ELEMENT
2y 10m to grant Granted Oct 13, 2026
Patent 12748249
POLARIZING PLATE AND OPTICAL DISPLAY DEVICE COMPRISING SAME
2y 7m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
98%
Grant Probability
99%
With Interview (+2.6%)
Low
PTA Risk
Based on 45 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month